Genomic Vision is a publicly-traded company on the Euronext regulated market in Paris



Press release





Bagneux (France), October 11, 2017 – 5.45 pm (CEST) – Genomic Vision (FR0011799907 – GV), a company specializing in the development of diagnostic tests for the early detection of cancers and hereditary diseases, and in applications for life sciences research laboratories, announces that it has today presented the interim results of its clinical trial in HPV (human papillomavirus) at the Eurogin 2017 (EUropean Research Organisation on Genital Infection and Neoplasia) annual congress in Amsterdam, the Netherlands.

The primary endpoint of the EXPL-HPV-002 study, initiated in July 2016, is to evaluate the integration of the HPV virus as a biomarker for diagnosing high-risk precancerous lesions requiring an appropriate treatment. Promising preliminary results were announced in May 2017 based on the interim analysis of 126 patients positively tested for at least one of the 14 high-risk HPV. They demonstrate that the integration of 14 high-risk human papillomaviruses (HR-HPV) detected by molecular combing serves as a relevant indicator of how severe the precancerous lesions are. To date, 472 patients between 25 and 65 years old have been enrolled in the study (including 164 patients with high-grade lesions and 31 with low-grade lesions) out of approximately 600 patients in total, and the final analysis of the results is expected in early 2018.

The interim results were presented today at the Eurogin congress during a session on molecular and biological markers by Dr. Vladimír Dvořák, Head Physician at the Brno Centre for Outpatient Gynecology and Primary Care in the Czech Republic and principal investigator for the study:The clinical results to date emphasize the importance of molecular combing in improving the detection of precancerous lesions of cervix. They naturally need to be confirmed in a larger number of patients, as the final statistical analysis requires 60 patients with low-grade lesions and 60 with high-grade lesions. If the final results are positive, molecular combing will become an additional efficient tool for a more accurate evaluation of the lesions’ severity, and hence of the risk of developing cervical cancer, thus enabling patients to receive the optimal care.

Anne Jacquet, Biomedical Research Director at Genomic Vision, adds:We are delighted with the substantial interest of the scientific community in our interim results presented today at Eurogin. It illustrates the need and importance of new diagnostic approaches in the detection of cervical cancer. The presentation of our results at the annual congress bringing together international and multidisciplinary experts in HPV demonstrates that all the advances allowing a predictive diagnostic of the appearance and progression of the disease are highly awaited.


Since 1994, the Eurogin annual congress has brought together researchers and clinicians to raise the scientific community’s awareness of diagnostic and prevention tools for genital infections and neoplasia. It is a multidisciplinary international congress on HPV attended by all scientific and industrial experts who share their expertise and opinion to define what the priorities should be with regards to the issue of HPV-induced cancer.




GENOMIC VISION is a company specialized in the development of diagnostic solutions for the early detection of cancers and serious genetic diseases and tools for life sciences research. Through the DNA Molecular Combing, a strong proprietary technology allowing the identification of genetic abnormalities, GENOMIC VISION supports the R&D productivity of pharmaceutical companies, leaders in the diagnostic industry and research labs.

The Company develops a strong portfolio of diagnostic tests (breast and colorectal cancers, myopathies) and analysis tools (DNA replication, biomarkers discovery, gene editing quality control). Based in Bagneux, near Paris, the Company employs approximately 60 people. GENOMIC VISION is a public company listed on compartment C of Euronext’s regulated market in Paris (Euronext: GV – ISIN: FR0011799907). For further information, please visit



Genomic Vision

Aaron Bensimon

Co-fondateur et Président du Directoire

Tél. : +33 1 49 08 07 50


Press Relations

Bruno Arabian

Tel. : +33 1 83 62 34 84


Investor Relations

Dušan Orešanský / Emmanuel Huynh

Tel. : +33 1 44 71 94 92

Membre des indices CAC® Mid & Small et CAC® All-Tradable



This press release contains implicitly or explicitly certain forward-looking statements concerning Genomic Vision and its business.

Such forward-looking statements are based on assumptions that Genomic Vision considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the  “Risk Factors” section in its Document de Reference filed with the French Autorité des Marchés Financiers (AMF) on March 28, 2017, under number R.17-009, available on the web site of Genomic Vision ( and to the development of economic conditions, financial markets and the markets in which Genomic Vision operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Genomic Vision or not currently considered material by Genomic Vision. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Genomic Vision to be materially different from such forward-looking statements.


This press release and the information contained herein do not constitute and should not be construed as an offer or an invitation to sell or subscribe, or the solicitation of any order or invitation to purchase or subscribe for Genomic Vision shares in any country. The distribution of this press release in certain countries may be a breach of applicable laws. The persons in possession of this press release must inquire about any local restrictions and comply with these restrictions.